MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-19-2022
Calliditas Therapeutics AB (publ) Revenue 2011-2025 | CALT
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Calliditas Therapeutics AB (publ)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 874 K | 185 M | - | - | - | - | - | - | - | - |
All numbers in SEK currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 185 M | 874 K | 92.9 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Drug manufacturers industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
80.8 M | - | - | $ 142 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
194 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
269 M | $ 1.2 | 0.42 % | $ 129 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
651 K | - | 7.5 % | $ 6.35 M | USA |
 |
Cronos Group
CRON
|
46.7 M | $ 2.67 | 0.19 % | $ 1.39 B | Canada |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
4.76 M | - | 0.86 % | $ 117 M | USA |
 |
Catalent
CTLT
|
4.38 B | - | - | $ 11.5 B | USA |
 |
Agile Therapeutics
AGRX
|
19.6 M | - | 10.11 % | $ 58.2 M | USA |
 |
DURECT Corporation
DRRX
|
8.55 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
317 M | - | -39.89 % | $ 27.7 M | USA |
 |
Aurora Cannabis
ACB
|
175 M | $ 4.32 | -3.79 % | $ 86.3 M | Canada |
 |
Endo International plc
ENDP
|
2.01 B | - | - | $ 28.9 M |  Irlanda |
 |
Zomedica Corp.
ZOM
|
25.2 M | - | -0.21 % | $ 98 M | USA |
 |
Evoke Pharma
EVOK
|
5.18 M | - | - | $ 36.6 M | USA |
 |
HEXO Corp.
HEXO
|
191 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
86 K | - | - | $ 55.5 M | USA |
 |
Emergent BioSolutions
EBS
|
1.05 B | $ 12.28 | -1.17 % | $ 629 M | USA |
 |
Athenex
ATNX
|
103 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
169 M | $ 21.57 | -0.12 % | $ 2.05 B |  France |
 |
Evolus
EOLS
|
266 M | $ 6.67 | -3.33 % | $ 414 M | USA |
 |
Harrow Health
HROW
|
130 M | $ 50.64 | 1.09 % | $ 1.65 B | USA |
 |
China Pharma Holdings
CPHI
|
4.53 M | $ 1.27 | -1.17 % | $ 22.2 M |  China |
 |
OrganiGram Holdings
OGI
|
160 M | $ 1.71 | -4.47 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
482 M | $ 5.22 | -1.14 % | $ 687 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
25 M | - | - | $ 193 M | Canada |
 |
Bausch Health Companies
BHC
|
8.76 B | $ 7.15 | -0.69 % | $ 2.61 B | Canada |
 |
Lannett Company
LCI
|
341 M | - | 1.15 % | $ 7.11 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
14.3 M | $ 3.66 | 1.25 % | $ 4.54 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
10.4 M | $ 4.02 | -2.31 % | $ 56.5 M | USA |
 |
Rockwell Medical
RMTI
|
83.6 M | $ 0.82 | -5.16 % | $ 19.1 M | USA |
 |
Pacira BioSciences
PCRX
|
542 M | $ 26.19 | -1.21 % | $ 1.21 B | USA |
 |
Sundial Growers
SNDL
|
920 M | $ 1.73 | -0.29 % | $ 3.37 M | Canada |
 |
PetIQ
PETQ
|
1.1 B | - | 1.64 % | $ 400 M | USA |
 |
Veru
VERU
|
16.9 M | $ 2.2 | -8.33 % | $ 297 M | USA |
 |
Jupiter Wellness
JUPW
|
702 K | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
4.37 B | $ 13.87 | 0.4 % | $ 1.91 B | USA |
 |
ProPhase Labs
PRPH
|
123 M | $ 0.45 | -13.46 % | $ 7.13 M | USA |
 |
cbdMD
YCBD
|
19.5 M | $ 1.46 | -14.41 % | $ 6.3 M | USA |
 |
Radius Health
RDUS
|
230 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
94.6 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
5.13 K | $ 4.41 | -2.22 % | $ 133 M | USA |
 |
OptiNose
OPTN
|
71 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
152 M | $ 9.56 | -3.82 % | $ 679 M | USA |
 |
PLx Pharma
PLXP
|
8.21 M | - | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
140 M | $ 0.62 | 6.08 % | $ 29.7 M | USA |
 |
Tilray
TLRY
|
627 M | $ 9.33 | -2.81 % | $ 5.77 B | Canada |
 |
TherapeuticsMD
TXMD
|
1.3 M | $ 1.67 | -4.02 % | $ 17.4 M | USA |